The Motley Fool

Why the ResMed share price is getting smoked

The ResMed Inc. (ASX: RMD) share price is down 10% today to follow on from last Friday’s 12% fall in another leg down on the back of its weaker-than-expected quarterly profit result delivered last Friday.

The company disappointed the market after revealing quarterly constant currency revenue growth of 9% to US$651.1 million translated into a flat adjusted profit of US$144.5 million and flat earnings per share of US$1.

The lack of bottom line growth combined with a ballooning debt pile and interest expenses have led investors to hit the sell button as the company flagged quarterly interest expenses around US$14 million per quarter higher over the six months ahead.

ResMed has spent around US$1.78 billion (A$2.5 billion) on acquisitions mainly in the popular software-as-a-service (SaaS) space over the last couple of years as its CEO pursues a strategy of making it a leader in cloud-based digitally connected healthcare solutions.

While this is an admirable strategy, SaaS businesses tend to boast lofty valuations thanks to their attractive economics and ResMed is now sporting a stretched balance sheet while its top line is not showing a huge return on investment for the shopping spree.

To be fair ResMed and its CEO have an absolutely superb long-term track record, so the market’s short-term impatience in lopping 20% off its value may be a good buying opportunity. Moreover, in sending the shares up 35% prior to last week’s result investors probably got carried away to the upside over the past year, just as they can also get carried away to the downside.

ResMed is one of three healthcare stocks on the local market I have regularly recommended to investors over the last 4 years, with the other two being CSL Limited (ASX: CSL) and Cochlear Ltd (ASX: COH). On current valuations I’d happily buy CSL and ResMed, but Cochlear shares still look too expensive to me.

Top 3 ASX Blue Chips To Buy For 2019

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2019."

Each one pays a fully franked dividend. The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor Tom Richardson owns shares of Cochlear Ltd., CSL Ltd., and ResMed Inc.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

NEW. Five Cheap and Good Stocks to Buy in 2019…

Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield…

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.

CLICK HERE FOR YOUR FREE REPORT!